Human biospecimen research: Experimental protocol and quality control tools

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 4, 2009, Pages 1017-1025

  Betsou, Fotini ^a   Barnes, Rebecca ^b   Burke, Thomas ^c   Coppola, Domenico ^d   DeSouza, Yvonne ^e   Eliason, James ^f   Glazer, Barbara ^g   Horsfall, David ^h   Kleeberger, Cynthia ⁱ   Lehmann, Sylvain ^j   Prasad, Anil ^k   Skubitz, Amy ^l   Somiari, Stella ^m   Gunter, Elaine ⁿ  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c DUKE UNIVERSITY   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Michigan Neonatal Biotrust   (United States)

^g IQVIA   (United States)

^h HANSON INSTITUTE   (Australia)

ⁱ SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^j INSTITUTE OF HUMAN GENETICS   (France)

^k UNIVERSITY OF ARIZONA   (United States)

^l UNIVERSITY OF MINNESOTA   (United States)

^m WINDBER RESEARCH INSTITUTE   (United States)

ⁿ Specimen Solutions LLC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

CANCER RESEARCH; CEREBROSPINAL FLUID; DATA ANALYSIS; EXPERIMENTATION; METABOLOMICS; NOTE; PLASMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEOMICS; QUALITY CONTROL; SAMPLING; STANDARDIZATION; TRANSCRIPTOMICS; URINE;

BIOLOGICAL MARKERS; BIOLOGICAL SPECIMEN BANKS; BIOMEDICAL RESEARCH; HUMANS; QUALITY CONTROL; RESEARCH DESIGN; SPECIMEN HANDLING;

EID: 66649124516     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-1231     Document Type: Note

References (39)

1. Carraro P, Plebani M. Errors in a stat laboratory: types and frequencies 10 years later. Clin Chem 2007;53:1338-1342 PubMed doi:10.1373/clinchem.2007. 088344. (Pubitemid 47020991)
2. Lippi G, Guidi GC, Mattiuzzi C, Plebani M. Preanalytical variability: the dark side of the moon in laboratory testing. Clin Chem Lab Med 2006;44:358-365 PubMed doi:10.1515/CCLM.2006.073.
3. Pepe MS, Etzioni R, FengZ, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-1061 PubMed doi:10.1093/jnci/93.14.1054. (Pubitemid 32717537)
4. Vaught JB. Blood collection, shipment, processing and storage. Cancer Epidemiol Biomarkers Prev 2006;15:1582-4. PubMed doi:10.1158/1055-9965.EPI-06- 0630. (Pubitemid 44497090)
5. Holland NT, Pfleger L, Berger E, Ho A, Bastaki M. Molecular epidemiology biomarkers-sample collection and processing considerations. Toxicol Appl Pharmacol 2005;206:261-268 PubMed doi:10.1016/j.taap.2004.10.024. (Pubitemid 40828246)
6. Landi MT, Caporaso N. Sample collection, processing and storage. IARC Sci Publ 1997;142:223-236 PubMed.
7. Riegman PHJ, Morente MM, Betsou F, DeBlasio P, Geary P. Biobanking for better healthcare. Mol Oncol 2008;2:213-222 doi:10.1016/j.molonc.2008.07.004.
8. Betsou F, Luzergues A, Carter A, et al. Toward norms for accreditation of biobanks for human health and medical research: compilation of existing guidelines into an ISO certification/accreditation norm-compatible format. Qual Assur J 2007;11:221-294 doi:10.1002/qaj.425.
9. Lengellé J, Panopoulos E, Betsou F. Soluble CD40 ligand as a biomarker for storage-related preanalytic variations of human serum. Cytokine 2008;44:275-282 PubMed doi:10.1016/j.cyto.2008.08.010.
10. Gutman S, Hackett J. Search for shortcuts on the critical path to market: US FDA perspective from the diagnostic side. Pharmacogenomics 2006;7:1223-1227 PubMed doi:10.2217/14622416.7.8.1223. (Pubitemid 46024185)
11. Goodsaid F, Fruech F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J 2007;9:E105-8. PubMed doi:10.1208/ aapsj0901010. (Pubitemid 46523058)
12. Rai AJ, Gelfand CA, Haywood BC, et al. HUPO Plasma Proteome Project specimen collection and handling: toward the standardization of parameters for plasma proteome samples. Proteomics 2005;5:3262-3277 PubMed doi:10.1002/pmic. 200401245. (Pubitemid 41192034)
13. Debey S, Schoenbeck U, Hellmich M, et al. Comparison of different isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses, on overall expression and the role of different cell types. Pharmacogenomics J 2004;4:193-207. PubMed doi:10.1038/sj.tpj.6500240. (Pubitemid 38786558)
14. Bernard AM. Biokinetics and stability aspects of biomarkers: recommendations for application in population studies. Toxicology 1995;101:65-71. PubMed doi:10.1016/0300-483X(95)03019-C.
15. Winn DM, Reichman ME, Gunter E. Epidemiologic issues in the design and use of biologic specimen banks. Epidemiol Rev 1990;12:56-70. PubMed.
16. NCCLS document H18- 4-Procedures for the handling and processing of blood specimens; approved guideline- 4th edition (in press). Pennsylvania (PA): NCCLS. In press 2008.
17. Institut National du Cancer (INCa). Recommandations pré- analytiques en protéomique clinique. Sérum, Prélè vement et Conservation. Boulogne Billancourt (France): INCa/ Société Française de Biologie Clinique; 2008.
18. Institut National du Cancer (INCa). Recommandations pré- analytiques en protéomique clinique. Plasma, Prélèvement et Conservation. Boulogne Billancourt (France): INCa/Société Française de Biologie Clinique; 2008.
19. Institut National du Cancer (INCa). Recommandations pré- analytiques en protéomique clinique. Urine, Prélèvement et Conservation. Boulogne Billancourt (France): INCa/Société Française de Biologie Clinique; 2008.
20. Institut National du Cancer (INCa). Recommandations pré- analytiques en protéomique clinique. LCR, Prélèvement et Conservation. Boulogne Billancourt (France): INCa/Société Française de Biologie Clinique; 2008.
21. American Society for Biochemistry and Molecular Biology. Bethesda (MD): American Society for Biochemistry and Molecular Biology. Guidelines for Preparing Manuscripts Describing Research in Clinical Proteomics; 2008. Available from: http://www.mcponline.org/cpmeeting/ProGuideIntro2.shtml.
22. Deutsch EW, Ball CA, Berman JJ, et al. Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE). Nat Biotechnol 2008;26:305-312 PubMed doi:10.1038/nbt1391.
23. Flower L, Ahuja RH, Humphries SE, Mohamed-Ali V. Effects of sample handlingon the stability of interleukin 6, tumour necrosis factor-alpha and leptin. Cytokine 2000;12:1712-1716 PubMed doi:10.1006/cyto.2000.0764.
24. Stanta G, Mucelli SP, Petrera F, Bonin S, Bussolati G. A novel fixative improves opportunities of nucleic acids and proteomic analyses in human archive's tissues. Diagn Mol Pathol 2006;15:115-23. PubMed doi:10.1097/00019606- 200606000-200700009 (Pubitemid 44350489)
25. Vincek V, Nassiri M, Nadji M, Morales AR. A tissue fixative that protects macromolecules (DNA, RNA and protein) and histomorphology in clinical samples. Lab Invest 2003;83:1427-1435 PubMed doi:10.1097/01.LAB.0000090154.55436.D1. (Pubitemid 37267826)
26. Lykidis D, Van Noorden S, ArmstrongA, et al. Novel zinc-based fixative for high quality DNA, RNA and protein analysis. Nucleic Acids Res 2007;35:e85. PubMed doi:10.1093/nar/gkm433.
27. FengZ, Prentice R, Srivastava S. Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. Pharmacogenomics 2004;5:709-719 PubMed doi:10.1517/14622416.5.6. 709. (Pubitemid 39236584)
28. Kaaks R, van der Tweel I, van Noord PA, Riboli E. Efficient use of biological banks for biochemical epidemiology: exploratory hypothesis testingby means of a sequential t-test. Epidemiology 1994;5:429-38. PubMed doi:10.1097/00001648-199407000-199500009 (Pubitemid 24197058)
29. Matthews JNS, Douglas G. Altman, MJ Campbell, P Royston. Analysis of serial measurements in medical research. BMJ 1990;300:230-235 PubMed. (Pubitemid 20045528)
30. Donner A. Linear regression analysis with repeated measurements. J Chronic Dis 1984;37:441-8. PubMed doi:10.1016/0021-9681(84)90027-90034
31. Betsou F, Roussel B, Guillaume N, Lefrere JJ. Long-term stability of coagulation variables: protein S as a biomarker for preanalytical storage-related variations in human plasma. Thromb Haemost 2009.
32. Chaigneau C, Cabioch T, Beaumont K, Betsou F. Serum biobank certification and the establishment of quality controls for biological fluids: examples of serum biomarker stability after temperature variation. Clin Chem Lab Med 2007;45:1390-1395 PubMed doi:10.1515/CCLM.2007.160. (Pubitemid 47557062)
33. Rouy D, Ernens I, Jeanty C, Wagner DR. Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem 2005;338:294-298 PubMed doi:10.1016/j.ab.2004.10.052. (Pubitemid 40312594)
34. Schoonenboom NS, Mulder C, Vanderstichele H, et al. Effects of processingand storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 2005;51:189-195 PubMed doi:10.1373/clinchem.2004.039735. (Pubitemid 40024030)
35. Carrette O, Burkhard PR, Hughes S, Hochstrasser DF, Sanchez JC. Truncated cystatin C in cerebrospinal fluid: Technical artefact or biological process? Proteomics 2005;5:3060-3065 PubMed doi:10.1002/pmic.200402039.
36. Battifora H. Assessment of antigen damage in immunohistochemistry. The vimentin internal control. Am J Clin Pathol 1991;96:669-671
37. Surjit M, Lal SK. Glycogen synthase kinase-3 phosphorylates and regulates the stability of P27kip1 protein. Cell Cycle 2007;6:580-588 PubMed. (Pubitemid 46440432)
38. Raleigh JA, Zeman EM, Rathman M, LaDine JK, Cline JM, Thrall DE. Development of an ELISA for the detection of 2-nitroimidazole hypoxia markers bound to tumour tissue. Int J Radiat Oncol Biol Phys 1992;22:403-405 PubMed.
39. Vonsattel JP, Del Amaya MP, Keller CE. Twenty-first century brain banking. Processing brains for research: the Columbia University methods. Acta Neuropathol 2008;115:509-32. PubMed doi:10.1007/s00401-007-0311-319